• 1
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.
  • 2
    Nimer SD. Myelodysplastic syndromes. Blood. 2008; 111: 4841-4851.
  • 3
    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189-199.
  • 4
    Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100: 2292-2302.
  • 5
    SwerdlowSH, CampoE, HarrisNL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: World Health Organization; 2008.
  • 6
    Ross SD, Allen IE, Probst CA, Sercus B, Crean SM, Ranganathan G. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist. 2007; 12: 1264-1273.
  • 7
    Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008; 87: 527-536.
  • 8
    Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin a as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer. 2009; 115: 706-715.
  • 9
    Hellstrom-Lindberg E, Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol. 2008; 45: 14-22.
  • 10
    Golshayan AR, Jin T, Maciejewski J, et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol. 2007; 137: 125-132.
  • 11
    Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008; 111: 574-582.
  • 12
    Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008; 26: 3607-3613.
  • 13
    Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002; 16: 1-6.
  • 14
    Musto P, Falcone A, Sanpaolo G, Bisceglia M, Matera R, Carella AM. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica. 2002; 87: 884-886.
  • 15
    Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001; 98: 958-965.
  • 16
    Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res. 2004; 28: 325-332.
  • 17
    Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008; 111: 86-93.
  • 18
    List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352: 549-557.
  • 19
    List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-1465.
  • 20
    Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008; 26: 2505-2511.
  • 21
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. V. 1.2009. Available at: Accessed March 9, 2009.
  • 22
    Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO classification and WPSS predict post-transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 2008; 112: 895-902.
  • 23
    Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002; 87: 1286-1306.
  • 24
    Bennett JM; MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008; 83: 858-861.
  • 25
    Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program. 2008: 166-175.
  • 26
    Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol. 2008; 20: 705-710.
  • 27
    Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 1997; 90: 1403-1409.
  • 28
    O'Dwyer K, Maslak P. Azacitidine and the beginnings of therapeutic epigenetic modulation. Expert Opin Pharmacother. 2008; 9: 1981-1986.
  • 29
    Kuendgen A, Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol. 2008; 87: 601-611.
  • 30
    Santini V, Gozzini A, Bosi A. Treatment options in myelodysplastic syndromes: a new frontier. J Chemother. 2008; 20: 291-296.
  • 31
    Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993; 7( suppl 1): 21-29.
  • 32
    Silverman LR, Holland JF, Demakos EP, et al. Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921 [abstract]. Ann Hematol. 1994; 68( suppl). Abstract 46.
  • 33
    Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20: 2441-2452.
  • 34
    Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 2429-2440.
  • 35
    Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006; 24: 3895-3903.
  • 36
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10: 223-232.
  • 37
    Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419-425.
  • 38
    Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25: 3503-3510.
  • 39
    Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008; 22: 538-543.
  • 40
    Silverman LR, Fenaux P, Mufti GJ, et al. The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients (pts) with myelodysplastic syndromes (MDS) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 227.
  • 41
    Mufti GJ, Fenaux P, Hellstrom-Lindberg E, et al. Treatment of high-risk MDS patients (pts) with −7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): effects on overall survival (OS) [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 7033.
  • 42
    Lim ZY, Ho AY, Samuel J, Hayden J, Garcia-Manero G, Mufti GJ. Outcomes of MDS patients with chromosome 7 abnormalities treated with 5-azacytidine [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 1449.
  • 43
    Grinblatt DL, Narang M, Malone JM III, Sweet DA, Dunne TS, Sullivan KA. Treatment of patients with low-risk myelodysplastic syndromes receiving azacitidine who are enrolled in AVIDA, a longitudinal patient registry [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 1646.
  • 44
    Lyons RM, Cosgriff T, Modi S, et al. Hematologic response to 3 alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009; 27: 1850-1856.
  • 45
    Muller-Thomas C, Schuster T, Peschel C, Gotze KS. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Ann Hematol. 2009; 88: 213-219.
  • 46
    Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008; 22: 1680-1684.
  • 47
    Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control. 2008; 15( suppl): 40-49.